Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study.
ABSTRACT In a double-blind controlled study lasting 8 weeks, 50 anxious psychoneurotic outpatients with a primary diagnosis of generalized anxiety or panic disorder were randomly assigned to alprazolam (n=30), a new benzodiazepine, or placebo (n=20), after a washout period of 1 week. Alprazolam at dosages between 0.25 and 3 mg/day was found to be significantly better than placebo in the treatment of either disorder. The finding that alprazolam was effective in the treatment of panic disorder is of interest as this diagnostic category is usually treated with tricyclic antidepressants or MAO inhibitors.
- Archives of General Psychiatry 05/1988; 45(5):413. DOI:10.1001/archpsyc.1988.01800290027004 · 13.75 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Because of their relatively short duration of action, most benzodiazepine anxiolytics require multiple daily dosing (two to four times per day) to maintain a consistent therapeutic benefit. The need for multiple daily doses can lead to interdose anxiety or brief periods of excessive side effects. These difficulties can both precipitate and exacerbate poor compliance with prescribed regimens. A new extended-release formulation of alprazolam (alprazolam XR) consistently maintains drug concentrations within the therapeutic range during a 12- to 24-hour duration of action. The potential advantages of alprazolam XR include improved compliance, less interdose anxiety, and a reduced risk of side effects.Current Therapeutic Research 09/1995; 56(9). DOI:10.1016/0011-393X(95)85099-6 · 0.45 Impact Factor